{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T17:29:24Z","timestamp":1772040564548,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Geriatr Med"],"DOI":"10.1007\/s41999-025-01165-4","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T18:59:53Z","timestamp":1740077993000},"page":"527-539","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Awareness of national dementia guidelines and management of oldest-old and frail people living with dementia: a European survey of geriatricians"],"prefix":"10.1007","volume":"16","author":[{"given":"Elke","family":"De Bondt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phaedra","family":"Locquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Gonz\u00e1lez","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinar","family":"Soysal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan D.","family":"Shenkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0265-9154","authenticated-orcid":false,"given":"Jos","family":"Tournoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"EuGMS Dementia Special Interest Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"issue":"10","key":"1165_CR1","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.amjmed.2018.01.022","volume":"131","author":"SA Gale","year":"2018","unstructured":"Gale SA, Acar D, Daffner KR (2018) Dementia. Am J Med 131(10):1161\u20131169. https:\/\/doi.org\/10.1016\/j.amjmed.2018.01.022","journal-title":"Am J Med"},{"issue":"9347","key":"1165_CR2","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/S0140-6736(02)11667-9","volume":"360","author":"K Ritchie","year":"2002","unstructured":"Ritchie K, Lovestone S (2002) The dementias. Lancet (London, England) 360(9347):1759\u20131766. https:\/\/doi.org\/10.1016\/S0140-6736(02)11667-9","journal-title":"Lancet (London, England)"},{"issue":"3","key":"1165_CR3","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3233\/JAD-191092","volume":"73","author":"Q Cao","year":"2020","unstructured":"Cao Q, Tan CC, Xu W, Hu H, Cao XP, Dong Q, Tan L, Yu JT (2020) The prevalence of dementia: a systematic review and meta-analysis. Journal of Alzheimer\u2019s disease: JAD 73(3):1157\u20131166. https:\/\/doi.org\/10.3233\/JAD-191092","journal-title":"Journal of Alzheimer's disease: JAD"},{"issue":"8","key":"1165_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.nrl.2016.02.016","volume":"32","author":"H Niu","year":"2017","unstructured":"Niu H, \u00c1lvarez-\u00c1lvarez I, Guill\u00e9n-Grima F, Aguinaga-Ontoso I (2017) Prevalence and incidence of Alzheimer\u2019s disease in Europe: A meta-analysis. Prevalencia e incidencia de la enfermedad de Alzheimer en Europa: metaan\u00e1lisis. Neurologia (Barcelona, Spain) 32(8):523\u2013532. https:\/\/doi.org\/10.1016\/j.nrl.2016.02.016","journal-title":"Neurologia (Barcelona, Spain)"},{"key":"1165_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/psychiatryint2020015","volume":"2","author":"B Cenko","year":"2021","unstructured":"Cenko B, Ozgo E, Rapaport P, Mukadam N (2021) Prevalence of dementia in older adults in central and eastern europe: a systematic review and meta-analysis. Psychiatry Int 2:191\u2013210. https:\/\/doi.org\/10.3390\/psychiatryint2020015","journal-title":"Psychiatry Int"},{"issue":"7","key":"1165_CR6","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1016\/S2468-2667(24)00120-8","volume":"9","author":"N Mukadam","year":"2024","unstructured":"Mukadam N, Wolters FJ, Walsh S, Wallace L, Brayne C, Matthews FE, Sacuiu S, Skoog I, Seshadri S, Beiser A, Ghosh S, Livingston G (2024) Changes in prevalence and incidence of dementia and risk factors for dementia: an analysis from cohort studies. The Lancet Public health 9(7):e443\u2013e460. https:\/\/doi.org\/10.1016\/S2468-2667(24)00120-8","journal-title":"The Lancet Public health"},{"issue":"5","key":"1165_CR7","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s41999-023-00846-2","volume":"14","author":"AH Dyer","year":"2023","unstructured":"Dyer AH, Dolphin H, Shenkin SD, Welsh T, Soysal P, Roitto HM, Religa D, Kennelly SP (2023) Emerging disease modifying therapies for older adults with Alzheimer disease: perspectives from the EuGMS special interest group in dementia. Euro Geriatr Med 14(5):919\u2013923. https:\/\/doi.org\/10.1007\/s41999-023-00846-2","journal-title":"Euro Geriatr Med"},{"issue":"2","key":"1165_CR8","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3892\/mmr.2019.10374","volume":"20","author":"K Sharma","year":"2019","unstructured":"Sharma K (2019) Cholinesterase inhibitors as Alzheimer\u2019s therapeutics (Review). Mol Med Rep 20(2):1479\u20131487. https:\/\/doi.org\/10.3892\/mmr.2019.10374","journal-title":"Mol Med Rep"},{"issue":"3","key":"1165_CR9","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s12640-013-9398-z","volume":"24","author":"CG Parsons","year":"2013","unstructured":"Parsons CG, Danysz W, Dekundy A, Pulte I (2013) Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer\u2019s disease. Neurotox Res 24(3):358\u2013369. https:\/\/doi.org\/10.1007\/s12640-013-9398-z","journal-title":"Neurotox Res"},{"issue":"11\u201312","key":"1165_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.18071\/isz.74.0379","volume":"74","author":"N Bal\u00e1zs","year":"2021","unstructured":"Bal\u00e1zs N, Bereczki D, Kov\u00e1cs T (2021) Cholinesterase inhibitors and memantine for the treatment of Alzheimer and non-Alzheimer dementias. A kolin\u00e9szter\u00e1z-g\u00e1tl\u00f3k \u00e9s a memantin haszn\u00e1lata Alzheimer- \u00e9s nem Alzheimer eredet\u0171 dementi\u00e1kban. Ideggyogyaszati szemle 74(11\u201312):379\u2013387. https:\/\/doi.org\/10.18071\/isz.74.0379","journal-title":"Ideggyogyaszati szemle"},{"issue":"2","key":"1165_CR11","doi-asserted-by":"publisher","first-page":"CD013306","DOI":"10.1002\/14651858.CD013306.pub2","volume":"2","author":"CE Battle","year":"2021","unstructured":"Battle CE, Abdul-Rahim AH, Shenkin SD, Hewitt J, Quinn TJ (2021) Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database Syst Rev 2(2):CD013306. https:\/\/doi.org\/10.1002\/14651858.CD013306.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"1165_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1176\/appi.ajp.2015.14121582","volume":"172","author":"C Stinton","year":"2015","unstructured":"Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, Cambridge V, Mason J, Thomas A, O\u2019Brien JT (2015) Pharmacological management of lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry 172(8):731\u2013742. https:\/\/doi.org\/10.1176\/appi.ajp.2015.14121582","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1165_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/jnnp-2014-307659","volume":"86","author":"HF Wang","year":"2015","unstructured":"Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF, Wang C, Tan MS, Tan L (2015) Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson\u2019s disease, Parkinson\u2019s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 86(2):135\u2013143. https:\/\/doi.org\/10.1136\/jnnp-2014-307659","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1165_CR14","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.2147\/NDT.S94430","volume":"11","author":"T Kishi","year":"2015","unstructured":"Kishi T, Matsunaga S, Iwata N (2015) Memantine for the treatment of frontotemporal dementia: a meta-analysis. Neuropsychiatr Dis Treat 11:2883\u20132885. https:\/\/doi.org\/10.2147\/NDT.S94430","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"1165_CR15","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s13311-023-01380-6","volume":"20","author":"KD Neylan","year":"2023","unstructured":"Neylan KD, Miller BL (2023) New approaches to the treatment of frontotemporal dementia. Neurotherapeutics: J Am Soc Exp NeuroTher 20(4):1055\u20131065. https:\/\/doi.org\/10.1007\/s13311-023-01380-6","journal-title":"Neurotherapeutics: J Am Soc Exp NeuroTher"},{"issue":"11","key":"1165_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11940-014-0319-0","volume":"16","author":"RM Tsai","year":"2014","unstructured":"Tsai RM, Boxer AL (2014) Treatment of frontotemporal dementia. Curr Treat Options Neurol 16(11):319. https:\/\/doi.org\/10.1007\/s11940-014-0319-0","journal-title":"Curr Treat Options Neurol"},{"issue":"7","key":"1165_CR17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nrneurol.2013.105","volume":"9","author":"Z Yang","year":"2013","unstructured":"Yang Z, Slavin MJ, Sachdev PS (2013) Dementia in the oldest old. Nat Rev Neurol 9(7):382\u2013393. https:\/\/doi.org\/10.1038\/nrneurol.2013.105","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"1165_CR18","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1093\/gerona\/glt051","volume":"68","author":"MJ Slavin","year":"2013","unstructured":"Slavin MJ, Brodaty H, Sachdev PS (2013) Challenges of diagnosing dementia in the oldest old population. J Gerontol. Series A, Biol Sci Med Sci 68(9):1103\u20131111. https:\/\/doi.org\/10.1093\/gerona\/glt051","journal-title":"J Gerontol. Series A, Biol Sci Med Sci"},{"key":"1165_CR19","unstructured":"Dementia in Europe Yearbook 2019. Estimating the prevalence of dementia in Europe. Alzheimer Europe. 2019. https:\/\/www.alzheimer-europe.org\/sites\/default\/files\/alzheimer_europe_dementia_in_europe_yearbook_2019.pdf. Accessed 31 Aug 2024"},{"issue":"4","key":"1165_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/alzrt181","volume":"5","author":"RC Gardner","year":"2013","unstructured":"Gardner RC, Valcour V, Yaffe K (2013) Dementia in the oldest old: a multi-factorial and growing public health issue. Alzheimer\u2019s Res Ther 5(4):27. https:\/\/doi.org\/10.1186\/alzrt181","journal-title":"Alzheimer's Res Ther"},{"issue":"6","key":"1165_CR21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jamda.2013.03.022","volume":"14","author":"JE Morley","year":"2013","unstructured":"Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, Cesari M, Chumlea WC, Doehner W, Evans J, Fried LP, Guralnik JM, Katz PR, Malmstrom TK, McCarter RJ, Gutierrez Robledo LM, Rockwood K, von Haehling S, Vandewoude MF, Walston J (2013) Frailty consensus: a call to action. J Am Med Dir Assoc 14(6):392\u2013397. https:\/\/doi.org\/10.1016\/j.jamda.2013.03.022","journal-title":"J Am Med Dir Assoc"},{"issue":"11","key":"1165_CR22","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.jamda.2022.01.084","volume":"23","author":"LG Koria","year":"2022","unstructured":"Koria LG, Sawan MJ, Redston MR, Gnjidic D (2022) The prevalence of frailty among older adults living with dementia: a systematic review. J Am Med Dir Assoc 23(11):1807\u20131814. https:\/\/doi.org\/10.1016\/j.jamda.2022.01.084","journal-title":"J Am Med Dir Assoc"},{"issue":"7","key":"1165_CR23","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/S2666-7568(23)00088-0","volume":"4","author":"JB Schwartz","year":"2023","unstructured":"Schwartz JB (2023) Representative enrolment of older adults in clinical trials: the time is now. Lancet Healthy Longev 4(7):e301\u2013e303. https:\/\/doi.org\/10.1016\/S2666-7568(23)00088-0","journal-title":"Lancet Healthy Longev"},{"key":"1165_CR24","doi-asserted-by":"publisher","DOI":"10.1590\/1980-5764-DN-2023-0051","volume":"18","author":"BRF de Santana","year":"2024","unstructured":"de Santana BRF, Borim FSA, de Assump\u00e7\u00e3o D, Neri AL, Yassuda MS (2024) Frailty and functional status among older adults with cognitive impairment: data from the second wave of the FIBRA study. Dementia Neuropsychologia 18:e20230051. https:\/\/doi.org\/10.1590\/1980-5764-DN-2023-0051","journal-title":"Dementia Neuropsychologia"},{"issue":"6","key":"1165_CR25","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1111\/bcp.15211","volume":"88","author":"LE Davies","year":"2022","unstructured":"Davies LE, Kingston A, Todd A, Hanratty B (2022) Is polypharmacy associated with mortality in the very old: findings from the Newcastle 85+ Study. Br J Clin Pharmacol 88(6):2988\u20132995. https:\/\/doi.org\/10.1111\/bcp.15211","journal-title":"Br J Clin Pharmacol"},{"key":"1165_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.exger.2019.02.019","volume":"120","author":"P Soysal","year":"2019","unstructured":"Soysal P, Perera G, Isik AT, Onder G, Petrovic M, Cherubini A, Maggi S, Shetty H, Molokhia M, Smith L, Stubbs B, Stewart R, Veronese N, Mueller C (2019) The relationship between polypharmacy and trajectories of cognitive decline in people with dementia: a large representative cohort study. Exp Gerontol 120:62\u201367. https:\/\/doi.org\/10.1016\/j.exger.2019.02.019","journal-title":"Exp Gerontol"},{"key":"1165_CR27","unstructured":"Global action plan on the public health response to dementia 2017\u20132025. World Health Organization. https:\/\/www.who.int\/publications\/i\/item\/9789241513487. Accessed 7 Nov 2022"},{"key":"1165_CR28","unstructured":"Maladie d\u2019Alzheimer et maladies apparent\u00e9es: diagnostic et prise en charge. Recommandations. 2011. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2011-12\/recommandation_maladie_d_alzheimer_et_maladies_apparentees_diagnostic_et_prsie_en_charge.pdf. Accessed 5 Oct 2022"},{"key":"1165_CR29","unstructured":"Richtlijn: Diagnostiek van dementie in de huisartsenpraktijk. 2020. https:\/\/www.dementie.be\/wp-content\/uploads\/2020\/01\/2020-Richtlijn-dementie-cebam-validated.pdf. Accessed 20 Sept 2022"},{"key":"1165_CR30","unstructured":"Nationella riktlinjer f\u00f6r v\u00e5rd och omsorg vid demenssjukdom. St\u00f6d f\u00f6r styrning och ledning. 2017. https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/nationella-riktlinjer\/2017-12-2.pdf. Accessed 26 Sept 2022"},{"key":"1165_CR31","unstructured":"Medizinische Leitlinie f\u00fcr die integrierte Versorgung Demenzerkrankter. Besser leben mit demenz. 2011. https:\/\/www.sozialversicherung.at\/cdscontent\/load?contentid=10008.714837&version=1391184725. Accessed 4 Oct 2022"},{"key":"1165_CR32","unstructured":"Dementia pathways. https:\/\/www.hse.ie\/eng\/dementia-pathways\/about\/. Accessed 28 Sept 2022"},{"key":"1165_CR33","unstructured":"Muistisairaudet. K\u00e4yp\u00e4 hoito -suositus. 2023. https:\/\/www.kaypahoito.fi\/hoi50044#s18. Accessed 29 Sept 2022"},{"key":"1165_CR34","unstructured":"DEUSCHL, G\u00fcnther, et al. S3-Leitlinie demenzen. Deutsche Gesellschaft f\u00fcr Neurologie, Hrsg. Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie, 2016, 24:33. https:\/\/secure.musiktherapie.de\/fileadmin\/user_upload\/medien\/pdf\/leitlinien\/LL-Methode_Evidenztab-16_02_10.pdf. Accessed 5 Oct 2022"},{"key":"1165_CR35","unstructured":"Sindrome Demenza Diagnosi e trattamento. Consiglio Sanitario Regionale. Regione Toscana. 2011. https:\/\/www.regione.toscana.it\/documents\/10180\/320308\/Sindrome%20demenza_1.pdf\/958f90f9-f94e-4095-a03a-d51293b9d47e. Accessed 29 Sept 2022"},{"key":"1165_CR36","unstructured":"Diagnostiek dementie. Nederlandse Vereniging voor Klinische Geriatrie. 2014. https:\/\/richtlijnendatabase.nl\/richtlijn\/dementie\/diagnostiek_dementie.html. Accessed 29 Sept 2022"},{"key":"1165_CR37","unstructured":"Ghid de diagnostic \u015fi tratament \u00een demen\u0163e. Romanian Society of Neurology and the Alzheimer society. 2019. https:\/\/psihiatriebucuresti.ro\/ghid-de-diagnostic-si-tratament-in-demente\/. Accessed 27 Sept 2022"},{"key":"1165_CR38","unstructured":"Dementia: assessment, management and support for people living with dementia and their carers. NICE guideline. 2018. https:\/\/www.nice.org.uk\/guidance\/ng97\/resources\/dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109. Accessed 14 Mar 2023"},{"issue":"3","key":"1165_CR39","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.6.3.e34","volume":"6","author":"G Eysenbach","year":"2004","unstructured":"Eysenbach G (2004) Improving the quality of web surveys: the checklist for reporting results of internet E-surveys (CHERRIES). J Med Internet Res 6(3):e34. https:\/\/doi.org\/10.2196\/jmir.6.3.e34","journal-title":"J Med Internet Res"},{"key":"1165_CR40","unstructured":"Miles, M. B., Huberman, M. A., Saldana, J. Qualitative Data Analysis. A Methods Sourcebook. Fourth Edition. https:\/\/us.sagepub.com\/en-us\/nam\/qualitative-data-analysis\/book246128. Accessed 23 May 2024"},{"key":"1165_CR41","unstructured":"Dementia Management. 2018 Implementation Update. American Medical Association, American Academy of Neurology Institute and American Psychiatric Association. 2018. https:\/\/www.aan.com\/siteassets\/home-page\/policy-and-guidelines\/quality\/quality-measures\/2018-dementia-management-measures.pdf. Accessed 11 May 2023"},{"issue":"8","key":"1165_CR42","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, Hansson O, Ho C, Jagust W, McDade E, Molinuevo JL, Okonkwo OC, Pani L, Rafii MS, Scheltens P, Siemers E, Snyder HM, Sperling R, Teunissen CE, Carrillo MC (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: alzheimer\u2019s association workgroup. Alzheimer\u2019s Dementia 20(8):5143\u20135169. https:\/\/doi.org\/10.1002\/alz.13859","journal-title":"Alzheimer's Dementia"},{"key":"1165_CR43","unstructured":"Multimorbidity: clinical assessment and management. NICE guideline. 2016. https:\/\/www.nice.org.uk\/guidance\/NG56\/. Accessed 4 Oct 2022"},{"key":"1165_CR44","unstructured":"Model of care for Dementia in Ireland. 2023. https:\/\/www.hse.ie\/eng\/services\/publications\/olderpeople\/model-of-care-for-dementia-in-ireland.pdf. Accessed 4 Apr 2023"},{"key":"1165_CR45","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1471-2377-11-57","volume":"11","author":"M Farlow","year":"2011","unstructured":"Farlow M, Veloso F, Moline M, Yardley J, Brand-Schieber E, Bibbiani F, Zou H, Hsu T, Satlin A (2011) Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer\u2019s disease. BMC Neurol 11:57. https:\/\/doi.org\/10.1186\/1471-2377-11-57","journal-title":"BMC Neurol"},{"key":"1165_CR46","unstructured":"Existing and emerging technologies used for decontamination of the healthcare environment: Evidence Grading and Recommendations. National Services Scotland. 2017. https:\/\/www.nss.nhs.scot\/media\/2228\/evidence-grading-v10.pdf. Accessed 11 Nov 2022"},{"key":"1165_CR47","unstructured":"Plan Integral de Alzheimer y otras Demencias. 2019\u20132023. Ministerio de Sanidad, Consumo y Bienestar social. https:\/\/www.sanidad.gob.es\/profesionales\/saludPublica\/docs\/Plan_Integral_Alhzeimer_Octubre_2019.pdf. Accessed 5 Jan 2025"},{"issue":"11","key":"1165_CR48","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/ageing\/afae250","volume":"53","author":"E Fabrizi","year":"2024","unstructured":"Fabrizi E, Ancidoni A, Locuratolo N, Piscopo P, Della Gatta F, Salemme S, Pani SM, Marconi D, Vignatelli L, Sagliocca L, Caffarra P, Secreto P, Guaita A, Stracciari A, Vanacore N, Lacorte E, Guideline Working Group (2024) The Italian guideline on diagnosis and treatment of dementia and mild cognitive impairment. Age Ageing 53(11):250. https:\/\/doi.org\/10.1093\/ageing\/afae250","journal-title":"Age Ageing"},{"issue":"1","key":"1165_CR49","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13195-018-0457-9","volume":"10","author":"KX Dou","year":"2018","unstructured":"Dou KX, Tan MS, Tan CC, Cao XP, Hou XH, Guo QH, Tan L, Mok V, Yu JT (2018) Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer\u2019s disease: a network meta-analysis of 41 randomized controlled trials. Alzheimer\u2019s research & therapy 10(1):126. https:\/\/doi.org\/10.1186\/s13195-018-0457-9","journal-title":"Alzheimer's research & therapy"},{"issue":"8","key":"1165_CR50","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archneurol.2011.69","volume":"68","author":"LS Schneider","year":"2011","unstructured":"Schneider LS, Dagerman KS, Higgins JP, McShane R (2011) Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 68(8):991\u2013998. https:\/\/doi.org\/10.1001\/archneurol.2011.69","journal-title":"Arch Neurol"},{"issue":"9","key":"1165_CR51","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.3390\/ijms21093272","volume":"21","author":"MT Kabir","year":"2020","unstructured":"Kabir MT, Uddin MS, Mamun AA, Jeandet P, Aleya L, Mansouri RA, Ashraf GM, Mathew B, Bin-Jumah MN, Abdel-Daim MM (2020) Combination drug therapy for the management of Alzheimer\u2019s disease. Int J Mol Sci 21(9):3272. https:\/\/doi.org\/10.3390\/ijms21093272","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1165_CR52","doi-asserted-by":"publisher","first-page":"CD003154","DOI":"10.1002\/14651858.CD003154.pub6","volume":"3","author":"R McShane","year":"2019","unstructured":"McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, Maayan N, Ware J, Debarros J (2019) Memantine for dementia. Cochrane Database Syst Rev 3(3):CD003154. https:\/\/doi.org\/10.1002\/14651858.CD003154.pub6","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1165_CR53","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s41999-023-00821-x","volume":"14","author":"GE Portlock","year":"2023","unstructured":"Portlock GE, Smith MD, van Poelgeest EP, Welsh TJ, EuGMS Task and Finish Group on FRIDs(Fall-Risk-Increasing Drugs) (2023) Therapeutic dilemmas: cognitive enhancers and risk of falling in older adults-a clinical review. Euro Geriatr Med 14(4):721\u2013732. https:\/\/doi.org\/10.1007\/s41999-023-00821-x","journal-title":"Euro Geriatr Med"},{"issue":"18","key":"1165_CR54","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJM199710303371806","volume":"337","author":"ME Tinetti","year":"1997","unstructured":"Tinetti ME, Williams CS (1997) Falls, injuries due to falls, and the risk of admission to a nursing home. N Engl J Med 337(18):1279\u20131284. https:\/\/doi.org\/10.1056\/NEJM199710303371806","journal-title":"N Engl J Med"},{"issue":"6","key":"1165_CR55","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1532-5415.2011.03450.x","volume":"59","author":"DH Kim","year":"2011","unstructured":"Kim DH, Brown RT, Ding EL, Kiel DP, Berry SD (2011) Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. J Am Geriatr Soc 59(6):1019\u20131031. https:\/\/doi.org\/10.1111\/j.1532-5415.2011.03450.x","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"1165_CR56","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1080\/14740338.2017.1351540","volume":"16","author":"D Mohammad","year":"2017","unstructured":"Mohammad D, Chan P, Bradley J, Lanct\u00f4t K, Herrmann N (2017) Acetylcholinesterase inhibitors for treating dementia symptoms\u2014a safety evaluation. Expert Opin Drug Saf 16(9):1009\u20131019. https:\/\/doi.org\/10.1080\/14740338.2017.1351540","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"1165_CR57","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3233\/JAD-140837","volume":"43","author":"MS Tan","year":"2015","unstructured":"Tan MS, Yu JT, Tan CC, Wang HF, Meng XF, Wang C, Jiang T, Zhu XC, Tan L (2015) Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimer\u2019s Dis: JAD 43(2):589\u2013603. https:\/\/doi.org\/10.3233\/JAD-140837","journal-title":"J Alzheimer's Dis: JAD"},{"issue":"2","key":"1165_CR58","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(19)30153-X","volume":"19","author":"JP Taylor","year":"2020","unstructured":"Taylor JP, McKeith IG, Burn DJ, Boeve BF, Weintraub D, Bamford C, Allan LM, Thomas AJ, O\u2019Brien JT (2020) New evidence on the management of Lewy body dementia. The Lancet Neurol 19(2):157\u2013169. https:\/\/doi.org\/10.1016\/S1474-4422(19)30153-X","journal-title":"The Lancet Neurol"},{"issue":"2","key":"1165_CR59","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.cger.2020.01.001","volume":"36","author":"JG Goldman","year":"2020","unstructured":"Goldman JG, Sieg E (2020) Cognitive impairment and dementia in parkinson disease. Clin Geriatr Med 36(2):365\u2013377. https:\/\/doi.org\/10.1016\/j.cger.2020.01.001","journal-title":"Clin Geriatr Med"},{"issue":"9","key":"1165_CR60","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S1474-4422(07)70195-3","volume":"6","author":"H Kavirajan","year":"2007","unstructured":"Kavirajan H, Schneider LS (2007) Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. The Lancet Neurol 6(9):782\u2013792. https:\/\/doi.org\/10.1016\/S1474-4422(07)70195-3","journal-title":"The Lancet Neurol"},{"issue":"4","key":"1165_CR61","doi-asserted-by":"publisher","first-page":"174","DOI":"10.5694\/mja2.50015","volume":"210","author":"E Reeve","year":"2019","unstructured":"Reeve E, Farrell B, Thompson W, Herrmann N, Sketris I, Magin PJ, Chenoweth L, Gorman M, Quirke L, Bethune G, Hilmer SN (2019) Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. Med J Aust 210(4):174\u2013179. https:\/\/doi.org\/10.5694\/mja2.50015","journal-title":"Med J Aust"},{"issue":"1","key":"1165_CR62","doi-asserted-by":"publisher","first-page":"e12099","DOI":"10.1002\/trc2.12099","volume":"8","author":"N Herrmann","year":"2022","unstructured":"Herrmann N, Ismail Z, Collins R, Desmarais P, Goodarzi Z, Henri-Bhargava A, Iaboni A, Kirkham J, Massoud F, Moser A, Silvius J, Watt J, Seitz D (2022) CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia. Alzheimer\u2019s Dementia (New York, N. Y.) 8(1):e12099. https:\/\/doi.org\/10.1002\/trc2.12099","journal-title":"Alzheimer's Dementia (New York, N. Y.)"},{"key":"1165_CR63","unstructured":"S3-Leitlinie Demenzen Langfassung, 2023 https:\/\/www.dgppn.de\/_Resources\/Persistent\/1f641e4edaf5c5d5a5114ee69146ba459a7da6b3\/S3-Leitlinie%20Demenzen_Langversion_2023_11_28_Final%20(003).pdf). Accessed 6 Jan 2025"}],"container-title":["European Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-025-01165-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41999-025-01165-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-025-01165-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T06:20:54Z","timestamp":1745302854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41999-025-01165-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":63,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["1165"],"URL":"https:\/\/doi.org\/10.1007\/s41999-025-01165-4","relation":{},"ISSN":["1878-7657"],"issn-type":[{"value":"1878-7657","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethical research commission\/KU Leuven: MP021976.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The study was anonymous so no informed consent was required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}